MedTrace Logo

Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome

NCT03089138 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-03-24

No results posted yet for this study

Summary

Efficacy and Safety of Regan Tangjiang for treating the common cold with wind-heat syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study

Conditions

  • Cold

Interventions

DRUG

Regan Tangjiang

The treatment duration is 3 consecutive days.

Sponsors & Collaborators

  • Beijing Da-an Bio-technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-31
Primary Completion
2018-03-31
Completion
2018-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03089138 on ClinicalTrials.gov